Evidence map›Paper›PMID 41826287›Full record

ArticleNature communications2026

A genus-wide interaction atlas across NS4B orthologues identifies a conserved role for UFMylation in orthoflavivirus replication.

Sreejith Rajasekharan, Viviana Andrea Barragan Torres, Yago Cortes Pinheiro Gomes, Lucas Wilken, Katharina Overhoff, Yen-Chia Lin, Shunmoogum A Patten, Satoru Watanabe, Laurent Chatel-Chaix, Pietro Scaturro

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sreejith RajasekharanLeibniz Institute of Virology, Hamburg, Germany.
Viviana Andrea Barragan TorresCentre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique, Laval, Québec, Canada.ORCID 0009-0009-9131-1114
Yago Cortes Pinheiro GomesCentre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique, Laval, Québec, Canada.
Lucas WilkenLeibniz Institute of Virology, Hamburg, Germany.ORCID 0000-0002-5678-3089
Katharina OverhoffLeibniz Institute of Virology, Hamburg, Germany.
Yen-Chia LinLeibniz Institute of Virology, Hamburg, Germany.
Shunmoogum A PattenCentre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique, Laval, Québec, Canada.ORCID 0000-0002-2782-3547
Satoru WatanabeProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
Laurent Chatel-ChaixCentre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique, Laval, Québec, Canada.ORCID 0000-0002-7390-8250
Pietro ScaturroLeibniz Institute of Virology, Hamburg, Germany. pietro.scaturro@leibniz-liv.de.ORCID 0000-0001-9098-3087

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 13GW0622Canada Foundation for Innovation (Fondation canadienne pour l'innovation) 37512Deutsche Forschungsgemeinschaft (German Research Foundation) 499961789Deutsche Forschungsgemeinschaft (German Research Foundation) 528559282Deutsches Zentrum für Infektionsforschung (German Center for Infection Research) TTU 01.812Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) PJT 190064Joachim Herz Stiftung (Joachim Herz Foundation) Innovate Academy
6 · The paper itself

Abstract

Orthoflavivirus infections represent an increasing public health burden, with several members of the genus emerging or re-emerging globally. Several pre-clinical studies identified the non-structural protein 4B (NS4B), as the most promising target for the development of potent direct-acting antivirals. However, its functional roles in viral replication are still elusive. Here, we employ an integrated proteomic approach to systematically identify cellular targets of NS4B across eight prototypic orthoflaviviruses and characterize their influence on the human proteome. Using this approach, we mapped high-confidence NS4B-interacting human proteins across the genus, underlying potentially divergent and convergent mechanisms of host adaptation across orthoflaviviruses spanning diverse pathologies and vector preferences. Among these, we unveil a novel function for UBA5, the E1-activating enzyme of the UFMylation pathway, in orthoflavivirus replication. Mechanistically, we map associations of distinct viral proteins with multiple members of the UFMylation pathway, which are selectively recruited to sites of viral replication to promote infectious particle production. Finally, we demonstrate that pharmacological inhibition of UFMylation exerts potent antiviral activity in vitro and in vivo. This integrative study provides a rational framework for a system-level understanding of orthoflavivirus NS4B effector functions and sheds light on a conserved and unconventional role for UFMylation in orthoflavivirus replication.

Indexed as

Viral Nonstructural ProteinsVirus ReplicationAnimalsHEK293 CellsHost-Pathogen InteractionsHumansProteomeProteomicsUbiquitin-Activating EnzymesNS4B protein, flavivirusProteomeUbiquitin-Activating EnzymesViral Nonstructural Proteins

Identifiers

PMID41826287
PMCPMC12992610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.